Business Wire

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Share

Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and HMNC Brain Health GmbH (“HMNC”), a global precision psychiatry biopharma company, announced today a strategic collaboration to develop Spruce’s investigational product candidate, tildacerfont, a second-generation CRF1 receptor antagonist, with HMNC’s companion diagnostic, the proprietary Cortibon Genetic Selection Tool (“Cortibon”), for the treatment of MDD.

“We believe that Cortibon has the potential to enable tildacerfont to be advanced as a precision therapeutic for personalized medicine in patients with MDD,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences. “Hyperactive corticotropin-releasing factor (CRF) neurotransmission and CRF1 receptor signal transduction are critical mechanisms for stress pathophysiology that may lead to major depression. Tildacerfont may mediate responses to stress, which has the potential to address up to 50% of the MDD patients worldwide using Cortibon. We are excited to collaborate with HMNC and initiate a Phase 2 proof-of-concept study of tildacerfont and Cortibon for the treatment of MDD later this year.”

“Treatment of MDD is hampered by patient heterogeneity, meaning many patients will fail to respond adequately to currently used therapies. HMNC’s collaboration with Spruce marks a significant step forward in our mission to bring innovative treatments to patients with depression. Combining our companion diagnostic with Spruce’s promising therapeutic offers a new avenue for precision psychiatry,” said Dr. Maximilian Doebler, Chief Business Officer, HMNC. “Traditional treatments often fall short, trapping patients in a costly trial-and-error cycle. Our platform uses genetic markers to predict responses to psychiatric medications, potentially enhancing treatment efficacy and reducing costs. This collaboration represents a new era in mental health management.”

Under the agreement, HMNC will fund and conduct a Phase 2 proof-of-concept study of tildacerfont in MDD patients, who will be screened using Cortibon. Spruce has an option to in-license exclusive worldwide rights to Cortibon after completion of the study, if results are positive. If Spruce exercises its option, it will be responsible for the future worldwide development and commercialization of tildacerfont and Cortibon for the treatment of MDD under a collaboration framework that leverages HMNC’s ongoing expertise in precision psychiatry and companion diagnostics. Pursuant to the license terms, HMNC would be entitled to receive certain milestone payments and tiered royalties on net sales of tildacerfont in MDD.

About Tildacerfont

Tildacerfont is a potent and highly selective, non-steroidal, oral antagonist of the CRF1 receptor, which is the receptor for corticotropin-releasing factor (CRF), a hormone that is secreted by the hypothalamus. The CRF1 receptor is abundantly expressed in the brain and pituitary gland, where it is the primary regulator of the hypothalamic–pituitary-adrenal (HPA) axis. By blocking the CRF1 receptor, tildacerfont has the potential to address hyperactive brain CRF neurotransmission and aberrant functioning of the HPA axis in patients with major depressive disorder (MDD). No drug-related serious adverse events have been reported related to tildacerfont treatment in completed studies.

About Cortibon

Cortibon is HMNC’s proprietary companion diagnostic, representing a potentially groundbreaking approach in the treatment of major depressive disorder (MDD). By utilizing genetic markers, Cortibon aims to identify MDD patients who are more likely to respond to CRF1 receptor antagonism, thereby enhancing treatment outcomes and reducing the trial-and-error period typical in depression treatment. Traditional treatments often lead to long onset times and insufficient response rates, trapping patients in a costly and prolonged trial-and-error cycle. Cortibon may dramatically shift this paradigm by improving treatment efficacy and reducing both costs and time.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF1 receptor antagonist, for the treatment of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS) and major depressive disorder (MDD). To learn more, visit www.sprucebio.com and follow us on X @Spruce_Bio, LinkedIn, Facebook and YouTube.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company headquartered in Munich, Germany, which is pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to higher remission rates in populations identified by companion diagnostics. The company develops unique pipelines for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD) and has three depression development programs in Phase 2. The company has presence in both Germany and the U.S. and is backed by a renowned global VC, several family officers, and a strategic healthcare investor. More information at www.hmnc-brainhealth.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the design, results, conduct, progress and timing of Spruce’s clinical trials; Spruce’s expectations regarding the initiation of the Phase 2 POC study of tildacerfont and Cortibon in patients with MDD in the fourth quarter of 2024; the potential for Cortibon to enable tildacerfont to be advanced as a precision therapeutics for MDD and other disorders; tildacerfont’s potential to mediate stress responses and Spruce’s product candidate, strategy and regulatory matters. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate”, “may,” “will”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Spruce Media
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
Katherine.Beach@inizioevoke.com
media@sprucebio.com

HMNC Media
Anne Donohoe
KCSA Strategic Communications
(732) 620-0033
hmncbrain@kcsa.com

Spruce Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
investors@sprucebio.com

HMNC Investors
Sophia Bashford
KCSA Strategic Communications
(347) 487-6788
sbashford@kcsa.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KAYTUS Unveils Cutting-Edge V3 Server Family for Next Open, Green and Scale-Up AI Infrastructure6.11.2024 09:53:00 CET | Press Release

KAYTUS, a leading provider of IT infrastructure, has announced the launch of its V3 server family. This latest lineup supports the powerful Intel® Xeon® 6 processors and AMD EPYC™ 9005 series processors, offering 17 versatile server models designed for general computing, multi-node configurations, critical computing, storage optimization, and rack-scale systems. The V3 server family is engineered with enhanced intelligence and groundbreaking cooling solutions, ensuring seamless support for diverse AI applications. Packed with advanced computing and storage technologies, it maximizes CPU bus bandwidth, memory bandwidth, and overall capacity. The dual-socket models boast up to 576 cores and clock speeds reaching 5.0 GHz, along with an impressive 136% boost in memory bandwidth. Performance tests reveal that in large-model AI inference scenarios, such as LLaMA2, the V3 series achieves up to 3x higher overall performance compared to its predecessor. This press release features multimedia. V

Kioxia Is Adopted for NEDO Project to Develop Manufacturing Technology for Innovative Memory Under the Post-5G System Infrastructure Project6.11.2024 09:39:00 CET | Press Release

Kioxia Corporation, a world leader in memory solutions, today announced that it has been adopted by Japan's national research and development agency, New Energy and Industrial Technology Development Organization (NEDO), for its groundbreaking proposal on the Development of Manufacturing Technology for Innovative Memory to enhance the post-5G information and communication system infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241106331046/en/ Memory category by bit density and read time (Graphic: Business Wire) In the post-5G information and communication era, AI is estimated to generate an unprecedented volume of data. This surge will likely escalate the data processing demands of data centers and increase power consumption. To address this, it is crucial that the next-generation memories facilitate rapid data transfer with high-performance processors while increasing capacity and reducing power consumption. A

PayPay and Alipay+ Extend Enhanced E-Wallet Payment Options to Over 3 Million Merchants Across Japan With Expanded Partnership6.11.2024 09:01:00 CET | Press Release

At the Singapore FinTech Festival 2024, PayPay, Japan's top QR payment operator, today announced an expanded partnership with Alipay+, Ant International’s cross-border mobile payment and digitalisation technology solution, broadening its merchant coverage network across Japan. By working with local partners including PayPay, Alipay+ will now connect over 3 million local merchants to the global payment ecosystem, enabling local businesses and payment partners to provide global visitors seamless and secure payment and travel experiences with their preferred domestic e-wallets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105682881/en/ Travellers can use Alipay+ wallets to scan the PayPay QR code for payment at the vast majority of PayPay stores. (Photo: Business Wire) Through this expanded partnership, travellers using Alipay+ payment partner apps will be able to scan PayPay QR codes to make payments at a wide range of me

Zilch Accelerates Growth and Halves Costs with Taktile’s Next-Generation Decision Platform6.11.2024 09:00:00 CET | Press Release

Zilch, the fintech payments innovator of the world’s first ad-subsidized payments network (ASPN), has revolutionized its underwriting infrastructure, achieving savings by reducing provider and usage costs by over half by transitioning to Taktile, a cutting-edge decisioning platform. This strategic shift not only enhances Zilch’s operational efficiency but also supports the company’s sustained growth in the highly competitive financial technology sector. Pioneering Change in Consumer Payments As a frontrunner in consumer payments, Zilch’s vision is to eliminate the high cost of consumer credit, for good. It empowers consumers to make purchases anywhere, anytime, without the burden of falling into revolving debt traps that cost consumers $150bn in interest and fees in just the US and UK alone. Having saved its 4m+ customers over $600m since launch in 2020 and as the first regulated credit product of its kind in the BNPL industry, Zilch’s ambitious target is to reduce that $150bn to zero,

Public Broadcaster ORF and ORS Group Extend Contract with SES at 19.2 degrees East6.11.2024 08:50:00 CET | Press Release

SES announced today it has extended its multi-year contracts with Austria’s largest media provider and public broadcaster ORF and its content distribution subsidiary ORS Group on SES’s prime TV neighbourhood at 19.2 degrees East. The agreement covers the satellite transmission of ORF's offerings, including the distribution of ORF 1 HD, ORF 2 HD, ORF III HD, ORF Sport plus HD, regional programmes from the Austrian states, as well as ORF's portfolio of radio channels. "Satellite remains the leading platform for TV reception in Austria and is therefore crucial for the distribution of ORF’s TV and radio programmes,” said Harald Kräuter, Director of Technology and Digitization at ORF. “With this contract extension, we are able to provide our audience with the highest quality programming via satellite as part of our distribution strategy, underscoring that linear TV will continue to be a key reception method for many years to come.” "For many years, SES has been a key partner in the distribu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye